newsfilter
← Latest News
PR Newswire·

TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

  • Faruqi & Faruqi, LLP is investigating potential securities claims against Tvardi Therapeutics, Inc. (NASDAQ: TVRD).
  • Tvardi shares fell over 80% on October 13, 2025, following disappointing preliminary data from the Phase 2 REVERT clinical trial of TTI-101 for idiopathic pulmonary fibrosis.
  • The study aimed to assess safety, pharmacokinetics, & lung function outcomes but failed to meet its goals regarding efficacy.
  • Preliminary results showed similar baseline characteristics across treatment arms except for percent predicted Forced Vital Capacity (FVC), which was lower in placebo-treated patients compared to TTI-101-treated arms.
  • Senior Partner James (Josh) Wilson is inviting investors who suffered significant losses to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
  • Additional information regarding the investigation is available at www.faruqilaw.com/TVRD.